To study the interaction of human factor Vlll (FVIII) with its various ligands, select regions of cDNA encoding FVlll light chain were cloned into the plasmid expression vector pET3B to overproduce FVlll protein fragments in the bacterium Escherichia coli. Partially purified FVlll protein fragments were used to produce monoclonal antibodies. One monoclonal antibody, 60-B, bound both an FVlll protein fragment (amino acid residues 1563 through 1909) and recombinant human FVIII, but not porcine FVIII. This antibody prevented FVIII-vWF binding and acted as an inhibitor in both the activated partial thromboplastin time (APTT) assay and a chromogenic substrate assay that measured factor Xa generation. The ability of the antibody to inhibit FVlll activity was N NORMAL individuals factor VI11 (FVIII) circulates I in a complex with von Willebrand factor (vWF).' Thrombin2 or factor Xa3 cleavage of FVIII results in the release of FVIIIa from vWF. The presence of vWF has been shown to stabilize the functional half-life of FVIII.4 Some sites of interaction between these two molecules have been localized on both FVIII and vWF. Limited protease digestion of vWF was used to localize the FVIII binding site on vWF to the fragment containing amino acid residues 1 through 272 of the mature vWF m01ecule.~ The epitope of a monoclonal anti-vWF antibody that inhibits FVIII-vWF binding has been mapped to residues 78 through 96 of the mature vWF.~ A binding site for vWF on FVIII has been identified both by monoclonal anti-FVIII antibodies that inhibit the interaction and also by FVIII deletion mutants. Monoclonal antibodies (MoAbs) were used to identify 10 amino acid residues in the FVIII light-chain activation peptide, 1675 through 1684, as part of the vWF binding site7*' (and this report). Deletion of FVIII B domain residues 771 through 1666 did not affect vWF binding: but deletion of residues 741 through 1689 abolished FVIII-vWF binding."
Some sites of interaction between these two molecules have been localized on both FVIII and vWF. Limited protease digestion of vWF was used to localize the FVIII binding site on vWF to the fragment containing amino acid residues 1 through 272 of the mature vWF m01ecule.~ The epitope of a monoclonal anti-vWF antibody that inhibits FVIII-vWF binding has been mapped to residues 78 through 96 of the mature vWF.~ A binding site for vWF on FVIII has been identified both by monoclonal anti-FVIII antibodies that inhibit the interaction and also by FVIII deletion mutants. Monoclonal antibodies (MoAbs) were used to identify 10 amino acid residues in the FVIII light-chain activation peptide, 1675 through 1684, as part of the vWF binding site7*' (and this report). Deletion of FVIII B domain residues 771 through 1666 did not affect vWF binding: but deletion of residues 741 through 1689 abolished FVIII-vWF binding."
Thrombin cleaves FVIII at heavy chain residues 372 and 740 to produce the 50-Kd and 40-Kd activated heavy-chain fragments, and at light-chain residue 1689." Loss of the thrombin site at residue 740 does not affect the generation of FVIIIa activity. However, the thrombin cleavage sites at residues 372, and possibly at 1689, are required for FVIII activity.'".' ' In this study we have used Escherichia coli to produce defined fragments of FVIII and then used the fragments to raise MoAbs. One of the antibodies, 60-B, was found to prevent thrombin cleavage at FVIII light chain residue 1689. This antibody also inhibited FVIII binding to vWF. The site of antibody binding was localized to FVIII light chain amino acid residues 1674 through 1684. The monoclonal anti-FVIII antibodies 60-B (this report), C4,7 and CLB:CAg-69' all bind within the same FVIII sequence and inhibit FVIII-vWF binding. However, 60-B, but neither C4 nor CLB:CAg-69, were reported to inhibit FVIII coagulant activity. In this work we also demonstrate that the 60-B antibody inhibits thrombin cleavage of FVIII light chain. 
MATERIALS AND METHODS
Select regions of the FVIII molecule were produced in E coli using a highly efficient expression vector." This expression system consists of three parts. The E coli strain, BL21(DE3), contains a lacW5 controlled bacteriophage T7 RNA polymerase gene located in the chromosome. The T7 RNA polymerase recognizes only T7 promoters and is unaffected by rifampicin, an inhibitor of endogenous E coli RNA polymerase. A plasmid, (pZysS), constituatively produces T7 lysozyme at low levels. The T7 lysozyme binds to and inactivates the small amount of T7 polymerase made constituatively in BL21(DE3). A second plasmid, pET3B, contains a truncated T7 coat protein gene under control of a T7 promoter. The cloned gene encoding the protein to be expressed is fused in frame to the 12th codon of the T7 coat protein gene. On induction with isopropyl thiogalactoside (IPTG), sufficient T7 polymerase is made to overcome lysozyme inactivation and to transcribe the coat protein fusion construct at a very high level. The relative level of this transcript can be increased by shutting off all other transcription with rifampicin.
Four FVIII light chain constructs were made in pET3B (Fig 1) . An FVIII cDNA encoding nucleotides 4852 to 7379 on a BamHI fragment was ligated into BamHI-digested pET3B. Transformants of DH5-(x were screened for correct orientation. The protein encoded in this construct, pET3B-8, contains FVIII amino acid residues 1563 through 2332, including 86 residues of the B domain and the complete FVIII light chain. Three additional clones were made by digesting the FVIII cDNA fragment with Bo11 and ligating each of the three resultant fragments into BamHI digested pET3B. The pET3B-16 construct encoded FVIII residues 1563 through 1909 and terminated after 18 vector-derived residues. The smallest protein was encoded by pET3B-10, residues Strains harboring these constructs were grown to an absorbance of 0.2 at 600 nm and induced by the addition of IPTG (1 mmollL, final concentration).
Cells were hawested 2 hours later, pelleted, and lysed by boiling in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) sample preparation buffer. The samples were analyzed on 10% SDS-polyacrylamide gelsi4 and blotted onto polyvinylidene difluoride paper (PVDF; Millipore, Bedford, MA)." The appropriate bands were cut out and the amino terminal protein sequence of the induced proteins was confirmed by protein sequencing.
The FVIII fragment of interest was overproduced and isolated by SDS-PAGE. SDS-polyacrylamide gels were briefly soaked in 4 m o l k sodium acetate" and the bands of interest cut out with a razor blade. The protein was electro-eluted from the gel and dialyzed into phosphate-buffered saline essentially as described by Goding." Alternatively, induced cells were lysed by sonication, and the cell pellets containing the insoluble FVIII fusion proteins were rinsed with 1% Triton X-100 (Sigma, St Louis, MO) in 0.02 mol/L trishydroxymethylaminomethane, 0.15 molL NaCl, pH 7.4, buffered saline (TBS). These pellets were then solubilized in 5 mol/L guanidine hydrochloride, 1 mmol/L EDTA, 1 mmol/L dithiothreitol, TBS, and chromatographed on an Ultragel AcA34 (LKB) column. The peak fractions representing the fusion protein were collected and pooled. Only the B-16 fusion protein remained soluble after dialysis into TBS. The gel-purified protein samples were mixed with Freund adjuvant and injected into mice for the production of MoAbs."
The primary screen of cell culture supernatants was performed by radioimmunoassay.'Y Supernatants from hybridoma cells were incubated in rabbit antimouse coated polystyrene tubes, and the capture of iodinated recombinant FVIII or iodinated fusion protein B-8 was measured.
Recombinant human FVIII and the FVIII cDNA were obtained from Genetics Institute (Boston, MA). Iodination of protein was performed by the iodine transfer method of Dewanjee et aLzo Human plasma vWF was isolated from frozen plasma prepared from blood anticoagulated with citrate-phosphateExpression conditions and protein isolation.
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dextrose (Fenwal, Deerfield, IL). The vWF was prepared as described by Thorell and Blomback" up The dissolved proteins were fractionated on a column of 4% agarose equilibrated in the same buffer. The fractions containing vWF, as determined by the ristocetin-induced platelet agglutination assay," were pooled and dialyzed versus TBS. Porcine factors IX, 11, X, IXa, and IIa were prepared as described by Lollar et al." Fab fragments were produced using the ImmunoPure Fab Preparation Kit from Pierce (Rockford, IL).
FVIII coagulant assays were performed as a modified activated partial thromboplastin time test." One unit of FVIII is defined as that amount of FVIII procoagulant activity found in 1 mL of pooled frozen normal human male plasma taken from 30 individuals.
The Bethesda assay" was used to determine anti-FVIII inhibitor activity of the murine antibodies. An assay measuring the binding of labeled FVIII on vWF-coated tubes was used as previously described." Western transfers onto PVDF paperz6 were probed with MoAbs and developed with rabbit antimouse 1g:alkaline phosphatase conjugates. Fluorescence polarization (FP) determinations were made on an On Line Systems (Jefferson, GA) modified SLM spectrofl~orometer.2~ The assay program was used with excitation at 340 nm and emission at 540 nm. Samples were assayed at 22°C in TBS within 5 minutes of mixing. Extended incubations did not alter the results. The fluorescence polarization value determined in each assay is an average of 720 samplings taken over a 2-minute period.
Factor Xa production by the enzymatic complex consisting of factor IXa, phosphatidyl-choline/phosphatidyl-serine (75%/25%) (PCPS) vesicles, calcium, and thrombinactivated FVIII (FVIIIa) was measured in a manner similar to that described by Lollar et a1. 28 Briefly, factor IXa (1 nmol/L), PCPS vesicles (15 pmol/L phosphorous), factor VI11 (0.14 nmol/L), and calcium (5 mmol/L) were incubated with thrombin (4 nmol/L) for 1 minute in TBS containing 0.01% polyethylene glycol-8000, in a microtiter plate (Immulon 1 Removawell Strip; Dynatech Laboratories, Inc, Chantilly, VA). Factor X was then added to the reaction mixture to 0.34 pmol/L. After 3 minutes the generation of factor Xa was stopped by the addition of EDTA to 0.13 mol/L. The amount of factor Xa present was determined by adding N-benzoyl-L-Ile-L-Glu-Gly-L-Arg-p-nitroanalide HCI and its methyl ester in equal amounts (S-2222) (concentration 0.4 mmol/L) to the above reaction mixture and, following the change in absorbance at 405 nm, using a Vmax kinetic microplate reader (Molecular Devices Corporation, Palo Alto, CA). The relative amount of factor Xa present was determined using SOFTmax, the software supplied with the plate reader.
To measure antibody inhibition of factor Xa generation, FVIII (0.28 nmol/L) was incubated with varying concentrations of 60-B IgG or Fab fragment in TBS containing 0.2 mg/mL bovine serum albumin for 30 minutes at room temperature. Factor IXa, Ca", PCPS, and thrombin were added and the assay performed as described previously.
Peptide synthesis. Synthetic peptides were prepared using RAMPS multiple peptide synthesis system (DuPont, Wilmington, DE). Rapid Amide resin, and fluorenylmethoxycarbonyl (FM0C)-amino acid pentafluorophenyl esters were used. After cleavage from the resin and deprotection of side chain groups with trifluoroacetic acid (TFA)-phenol, the peptides were purified by reversedphase high performance liquid chromatography (HPLC) (Vydac C,, column, aqueous TFA-acetonitrile gradient; Vydac, Hesperia, CA) and characterized by Edman degradation (Applied BiosysAssays.
Chromogenic assay.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From tems 470A sequencer; Applied Biosystems, Foster City, CA) and HPLC-identification of phenylthiohydantoin (PTH)-amino acids.
Peptides were dansylated before treatment with TFA-phenol. Approximately one third of each of the resin-bound peptides was removed and later treated with 0.5 mmol/L of dansylchloride in 0.1 mL of diisopropylethylamine and 3.0 mL of dimethylformamide. The resulting peptides were cleaved and deprotected with TFAphenol and purified by HPLC.
Approximately 100 pg of the synthetic peptide, corresponding to residues 1670 to 1684of human FVIII,
D E, was digested with 4 pg of tosylphenylalanine-chloromethylketone-treated trypsin in 5% ammonium bicarbonate for 4 hours at 37°C. The acidified reaction mixture was fractionated by HPLC, and the larger of the resulting peptides was isolated and shown to have the NH,-terminal sequence K E D F D. The mass of peptides used in the inhibition of binding experiments was estimated from the area of the absorbance peak at 220 nm from HPLC chromatograms. The FP studies were performed with peptides whose mass was determined gravimetricly on lyophilized samples.
RESULTS
Fusion proteins, purified from SDS-polyacrylamide gels, were used to inject mice for the Production of MoAbs. Fig 2) . Faint bands appearing on the Western blots in positions corresponding to albumin, B-10, or B-15 are considered artifacts as they are present in the absence of primary antibody (data not shown). This and subsequent work described below suggest that B-8 or B-16 may have been the immunogen for the antibody 60-B.
Each MoAb reacted with both recombinant human FVIII light chain and purified fusion proteins B-8 and B-16 on Western blots (Fig 2A and data not  shown) . On some Western blots, the 60-B antibody also reacts with material that is of higher molecular weight than intact FVIII light chain. Similar bands have been reported to be amino extensions of light chain present in recombiWestern blots. For
factor VIII.29 When thrombin-treated FVIII was probed, neither of the antibodies bound to the large FVIII light-chain fragment, residues 1690 through 2332. This result was consistent with antibody binding to the fragment (residues 1649 through 1689) released from FVIII light chain by thrombin cleavage. The released 41-amino acid residue fragment was not seen on the gels. It was also possible that the antibody-binding site spanned the thrombin-cleavage site. This question was resolved when a Western blot of thrombin-cleaved fusion protein B-16 was probed with the antibodies. This fusion protein is cleaved by thrombin into fragments of 15 Kd (FViII residues, 1563 through 1689) and 25 Kd (FVIII residues, 1690 through 1909). The MoAbs reacted with the 15-Kd fragment on the Western blots (Fig 2B, lanes 5 and 6, and data not shown) . Thus, the antibody-binding site for 60-B and 1-b was localized to residues 1649 through 1689. These antibodies were found not to react with porcine FVIII spotted onto nitrocellulose (data not shown).
These two anti-FVIII MoAbs were then assayed for binding to native FVIII. Each antibody was added to a rabbit antimouse-Ig-coated tube, and the subsequent capture of iodinated FVIII was measured (see Materials and Methods). Only 60-B reacted with native FVIII in this assay (data not shown).
The amino terminus of the FVIII light chain is involved in vWF binding.7,'2,30 Having determined that our MoAbs bound FVIII in this region, we tested them for their ability to inhibit FVIII-vWF interactions. The assay used to determine if 60-B blocked vWF: FVIII interaction was based on the amount of labeled FVIII that bound to a vWF coated tube. When the antibodies were included in the incubation, only 60-B was found to inhibit FVIII-vWF interactions. As seen in Fig 3A, FVIII-vWF binding was inhibited in a dose-dependent manner. In this assay 50% inhibition of FVIII binding required about 1.0 nmol/L antibody. Fab fragments also inhibited FVIII-vWF binding in a dose-dependent manner and at concentrations of combining sites essentially identical to whole IgG (Fig 3A) .
In a previous report, the anti-FVIII MoAb C4 was characterized as inhibiting the interaction of FVIII and vWF.~ Other monoclonal anti-FVIII antibodies that inhibit FVIII-vWF binding have also been described: CLA:CAg-58;' CLB-CAg 65, and CLB: CAg-69.8 Using synthetic peptides, the binding site on FVIII of the C4 and CLB:CAg-69 antibodies was localized to residues 1670 through 1684 and 1673 through 1689, respectively. Because the antibody described here, 60-B, also inhibited FVIII-vWF interactions, we synthesized a "human" peptide, encoding FVIII residues 1670 through 1684 (Fig 4) . We used this human peptide to test the possibility that the 60-B antibody bound to the same peptide as the C4 antibody. Because the antibody 60-B did not react with porcine FVIII, a second peptide, called the "hybrid" peptide, was made. The hybrid peptide contained a single amino acid substitution, glycine for aspartic acid, at residue 1681. This represents a change from the residue found in the human sequence to that found in the porcine sequence. This residue was chosen because it is well isolated from the other nonconserved residues.
The anti-FVIII MoAb 60-B was tested for reactivity to both the human and hybrid peptides. The binding of iodinated FVIII to antibody 60-B-coated tubes was inhibited by the addition of the human peptide. This inhibition Comparison of human and porcine FVlll light-chain activation peptide amino acid sequences. The amino acid sequence of human Wlll activation peptide residues 1649 through 1689 is shown as single-letter abbreviations. Directly below the human residues are the corresponding nonconsewed residues from porcine FVIII." The "human" peptide, 1670 through 1684, is underlined. The "hybrid peptide is identical t o the "human" peptide except for a glycine for aspartic acid substitution at residue 1681. The "tryptic" peptide is the trypsin digestion product of the "human" peptide.
was dose dependent with 50% inhibition at 0.09 pmol/L peptide. The hybrid peptide showed no inhibitory activity at
pmoI/L (data not shown).
Neither peptide, when present up to 4.5 pmol/L, could alter FVIII binding to vWF-coated tubes (data not shown). However, the human peptide reversed 60-B inhibition of FVIII binding to vWF in a dose-dependent manner (Fig 3B) . Total reversal of the inhibitory activity of 3 nmol/L of antibody required about 2 pmol/L of human peptide. Human peptide at 0.09 pmol/L was required to reverse 50% of the inhibitory activity. The hybrid peptide, at concentrations up to 2.5 pmol/L, did not influence the inhibitory effect of the antibody (Fig 3B) . These results indicated that the aspartic acid at residue 1681 makes an important contribution to the 60-B antibodybinding site on FVIII.
The human synthetic peptide was subjected to tryptic digestion to further characterize the anti-FVIII MoAb-binding site. The digestion products were isolated by HPLC and identified by sequence analysis. The peptide was cleaved between the lysines at residues 1673 and 1674 (Fig 4) . The binding of iodinated FVIII to antibody 60-Ekoated tubes was inhibited in a dosedependent manner by the trypsin digest fragment ("tryptic") of the human peptide containing only residues 1674 through 1684 (data not shown).
The interactions of the MoAbs with FVIII and the synthetic peptides were studied in the fluid phase by observing changes in the FP of dansylated peptides as a result of binding to an antibody. hybrid peptide (Fig 5A) . The 1-b antibody (1 pmol/L) reacted with the dansylated human peptide, and the human peptide, hybrid peptide, or tryptic peptides were effective competitors (Fig 5B) . The FP value of 2 pmol/L dansylated hybrid peptide was unchanged on addition of either antibody W3-3 or 60-B, but was reactive in a dose-dependent manner with 1-b (data not shown).
Anticoagulant activity of 60-8. We found that the 60-B antibody had an FVIII inhibitory activity of 9 Bethesda Units (BU)/mg IgG in the clotting assay. The inhibitory effect of 60-B on FVIII coagulant activity was further characterized by use of a defined multicomponent chro- Peptide Concentration, uM 1934 . A PRECUP, KLINE, AND FASS mogenic substrate assay (see Materials and Methods). This assay indirectly measures the amount of activated FVIII by monitoring the generation of factor Xa in the presence of factor IXa, factor X, PCPS vesicles, and calcium. The factor Xa produced releases p-nitroanaline (pNA) from the factor Xa substrate S-2222. The amount of pNA generated is proportional to the amount of thrombin-activated FVIII present. The MoAb 60-B was preincubated with 0.28 nmol/L FVIII for 30 minutes before thrombin activation. The inhibition of factor Xa generation by 60-B and its Fab is shown in Fig 6A. Complete inhibition of factor Xa activity occurred when antibody concentrations were over 100 nmol/L. Fifty-percent inhibition of factor Xa generation was seen near 1.0 nmol/L 60-B. The amount of Fab required for this degree of factor Xa inhibitory activity was approximately 10-fold higher. Addition of 1 p"l/L of antibody 60-B after the thrombin incubation had no effect on factor Xa generation (data not shown).
The antibody 60-B and vWF both appear to bind to FVIII in a mutually exclusive manner and could be expected to compete for binding. The amount of 60-B that inhibited factor Xa generation by 60% (3 nmol/L) was preincubated with FVIII in the presence of varying amounts of vWF (0.1 to 2.2 U/mL). As can be seen in Fig 6B, 0 .5 U/mL of vWF reversed the inhibition by 50%, and 2 U/mL completely reversed the antibody-induced inhibition of FVIII coagulant activity.
Gel analysis of thrombin cleavage. PAGE was used to
analyze the thrombin cleavage patterns of recombinant FVIII in the presence and absence of the antibody 60-B, or its Fab derivative (Fig 7) . Analysis of the gels indicated that both 60-B and its Fab derivative protect FVIII light chain from thrombin cleavage at residue 1689. This is evidenced by the absence of the 70-Kd activated FVIII light-chain band. Immunologic evidence suggests that the amino terminus of FVIII light chain may be involved in vWF binding to FVIII. In addition to the antibody described in this work, other laboratories have produced monoclonal anti-FVIII light-chain antibodies to this region of FVIII that inhibit FVIII-vWF interacti~n.'~~,~~ These studies suggest that the activation peptide of FVIII contains a highly antigenic region that contributes to the structures required for vWF Data from genetic analysis of FVIII deletion mutants'.'' show that FVIII light-chain amino acid residues 1666 through 1689 directly influence the vWF binding site because such mutants fail to bind vWF. This is in agreement with the antibody data which indicate that antibody binding to FVIII residues 1674 through 1684 inhibits FVIII-vWF binding' (and this report). The failure of peptides spanning this region to inhibit FVIII-vWF binding has not been explored here.
Relief of inhibition by vWF.

DISCUSSION
The plasma-based Bethesda assay indicated that the inhibitory activity of FVIII coagulant activity by 60-B is 9 BU/mg IgG. However, 60-B completely inhibited FVIII activity in a defined chromogenic assay, and this inhibition was reversible by addition of vWF at physiologic concentrations. Another MoAb that binds in this region" and polyclonal antibodies against a more proximal region of the activation peptide have also been shown to be weak inhibitorsM In addition to the inhibition of FVIII activity, the 60-B antibody also interferes with thrombin-mediated cleavage of FVIII light chain. There is contradictory evidence for the requirement of thrombin cleavage at FVIII residue 1689 for FVIII procoagulant activity. Studies on the site directed mutants of FVIII indicated that thrombin cleavages of FVIII at residues 372 and 1689 were essential for FVIII procoagulant activity.'" The FVIII molecule was found to be inactive if the light chain was not cleavable by thrombin. The FVIII from a severe hemophilia A patient has been characterized as having a cysteine substituted for the arginine at residue 1689,"5 and this amino acid substitution also results in the loss of thrombin cleavage of FVIII light chain and activity. Although this mutant FVIII bound vWF, neither its procoagulant activity nor its resistance to thrombin cleavage was altered by the presence of vWF.
It has also been suggested that the cleavage of FVIII light-chain residue 1689 is not essential for procoagulant activity, but may serve only to dissociate FVIII from the vWF." Cleavage of porcine FVIII by a snake venom at heavy-chain residues 372 and 740, but not at light-chain residue 1689, were sufficient to produce active FVIII in the absence of v W F .~ No active FVIII was produced if the snake venom cleavages were made in the presence of vWF. If thrombin cleavage at 1689 is not required for activity, then perhaps the cleavage product of the FVIII:60-B complex is analagous to the snake venom-activated FVIII inhibited by vWF; as the antibody would remain bound at or near the vWF binding site.
Any ligand bound near the a2:A3 junction may prevent the assembly of a productive factor X activating complex. The observation that 60-B binds to both synthetic peptides and to the smaller thrombin cleavage product of B-16 but does not inhibit FVIIIa after thrombin activation supports the observation that the a2 fragment does not participate in cofactor activity.'" The reported lack of procoagulant activity in the patient and site-directed mutant FVIIIs would then be attributable to the effect of a nonconservative amino acid substitution (I or C for R a t residue 1689) on the structure of FVIII and not due solely to the lack of thrombin cleavage.
We have shown that the 60-B inhibition of FVIII procoagulant activity can be blocked by the addition of physiologic amounts of vWF, and that 60-B blocks vWF binding of FVIII. However, the binding sites on FVIII for vWF and antibody 60-B appear not to be identical, because the FVIII associated with vWF is readily cleaved by thrombin, whereas MoAb 60-B protects FVIII from thrombin cleavage. For personal use only. on October 3, 2017. by guest www.bloodjournal.org From
